- Home
- ATNM
as 12-18-2024 12:31pm EST
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 56.5M | IPO Year: | N/A |
| Target Price: | $10.20 | AVG Volume (30 days): | 319.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $10.24 | Next Earning Date: | 11-14-2024 |
| Revenue: | $81,000 | Revenue Growth: | -92.14% |
| Revenue Growth (this year): | 186.1% | Revenue Growth (next year): | 19248.94% |
Latest Actinium Pharmaceuticals Inc. (Delaware) News
ATNM Breaking Stock News: Dive into ATNM Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
Associated Press Finance
a month ago
Actinium: Q3 Earnings Snapshot
PR Newswire
a month ago
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
Zacks
2 months ago
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Clinical Trials Arena
3 months ago
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
PR Newswire
3 months ago
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
MT Newswires
4 months ago
B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16
Associated Press Finance
4 months ago
Actinium: Q2 Earnings Snapshot
Compare ATNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATNM Actinium Pharmaceuticals Inc. (Delaware) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.